ALACHUA, FL--(Marketwired - December 15, 2016) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it will present "Intravenous Cyclodextrin Trials and Compassionate Use in Niemann Pick Type C Disease" at the 13th Annual WORLDSymposium, the premier scientific conference focused on lysosomal storage diseases. The presentation will focus on the use of Trappsol® Cyclo™, CTD's proprietary formulation of hydroxypropyl beta cyclodextrin, in compassionate use programs for over six years and will provide an update on CTD's two clinical trials using Trappsol® Cyclo™ intravenously to treat Niemann Pick Disease Type C (NPC) patients. CTD's clinical trials have been approved in the US (phase I) and in the EU (phase I/II), including in the United Kingdom and Sweden. The presentation will be made by Dr. Sharon Hrynkow, CTD's Senior Vice President for Medical Affairs, together with Dr. Caroline Hastings, UCSF Benioff Children's Hospital Oakland. Dr. Hastings is the first physician in the United State to treat NPC patients with Trappsol® Cyclo™ on a compassionate use basis. She serves as the Principal Investigator for the CTD US clinical trial and as Senior Clinical Advisor to the EU trial.
Date: Wednesday, February 15, 2017
Time 4:30 pm PST
Location: Manchester Grant Hyatt, San Diego, CA
"We are pleased to have the opportunity to report on our experience using Trappsol® Cyclo™ intravenously with patients in compassionate use programs, and on how the data has helped us launch two clinical trials with intravenous use of our product in NPC patients. This is an exciting time for our company and for the NPC patient community," said N. Scott Fine, CTD Chairman and CEO.
Niemann-Pick Disease Type C is a rare and fatal genetic disease that impacts primarily children but is increasingly diagnosed in older patients who may live with disability for many years. The disease impacts the brain and major organs through abnormal accumulation of cholesterol in cells.
About CTD Holdings:
CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company's Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol® Cyclo™, are in development. For additional information, visit the company's website: www.ctd-holdings.com
About the WORLDSymposium™:
The goal of the WORLDSymposia is to provide an interdisciplinary forum to explore and discuss specific areas of interest, research and clinical applicability related to lysosomal diseases. Each year, WORLDSymposia hosts a scientific meeting presenting the latest information from basic science, translational research, and clinical trials for lysosomal diseases. This symposium is designed to help researchers and clinicians to better manage and understand diagnostic options for patients with lysosomal diseases, identify areas requiring additional basic and clinical research, public policy and regulatory attention, and identify the latest findings in the natural history of lysosomal diseases. Additional information is available at the WorldSymposium website: www.worldsymposia.org
Safe Harbor Statement:
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.